Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $531,519.30 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Giles Richard Platford sold 31,083 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $531,519.30. Following the completion of the sale, the insider directly owned 315,838 shares of the company’s stock, valued at approximately $5,400,829.80. This trade represents a 8.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Trading Up 1.5%

NYSE:TAK opened at $17.64 on Friday. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The stock has a fifty day simple moving average of $16.57 and a 200-day simple moving average of $17.14. The company has a market capitalization of $56.53 billion, a PE ratio of 51.89 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The firm had revenue of $6.90 billion for the quarter. On average, equities research analysts expect that Takeda Pharmaceutical Co. will post 0.32 earnings per share for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in the business. Private Trust Co. NA grew its holdings in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of Takeda Pharmaceutical by 192.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after acquiring an additional 1,684 shares during the period. SHP Wealth Management purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter worth about $42,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after acquiring an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after acquiring an additional 1,292 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TAK has been the topic of several recent research reports. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.